This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Ratings

10 Best Biotech Stocks for

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology


Source: TheStreet Ratings

Best Investments for

Biotechnology News

With new stock option grants this week, Epizyme executives are sending an ugly message to aggrieved shareholders: We don't mind profiting from your pain.
2/11/16 12:00PM
Incyte is halting all clinical trials intended to expand the use of its blood cancer drug Jakafi into solid tumors due to an insufficient level of efficacy.
2/11/16 9:32AM
In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.
2/10/16 8:28AM
Frank comments and a warning from a doctor supervising pivotal brain cancer vaccine study for Northwest Bio are likely cause of sharp slide in stock price.
2/9/16 10:00AM
Someone needs to send MannKind executives a primer on the uses of Twitter hashtags.
2/4/16 8:43AM
Foster City, Calif.-based biotech giant Gilead announced a new $12 billion share repurchase plan on Tuesday night in conjunction with fourth-quarter earnings.
2/3/16 6:00AM
The disclosure that Pfizer shelved an Alzheimer's drug because of disappointing efficacy is driving down the market value of Axovant Sciences, which is developing a similar drug.
2/2/16 10:17AM
Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.
2/1/16 8:02AM
The list price for Merck's newly approved hepatitis C drug is lower than competing therapies from Gilead Sciences and Abbvie, which means a new price war could be heating up.
1/29/16 8:16AM
Celldex will announce the outcome of an interim analysis for a pivotal study of its brain tumor therapy Rintega within weeks.
1/28/16 8:45AM
The controversy over drug pricing factored into Biogen's revenue guidance for 2016.
1/27/16 11:41AM
Juno and Kite Pharma are under pressure Tuesday after U.S. government researchers published a study showing an off-the-shelf, engineered T-cell therapy could induce remissions in patients with blood cancers.
1/26/16 11:15AM
Biotech news and observations to start the week.
1/25/16 1:03PM
Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.
1/24/16 2:00PM

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

Markets

Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%
Top Rated Stocks Top Rated Funds Top Rated ETFs